Authors: B.K.M.Reddy, V.Lokesh, M.S.Vidyasagar, K.Shenoy, K.G.Babu, A.Shenoy, T.Naveen, Bindhu Joseph, R.Bonanthaya, Nanjundappa, P.P.Bapsy, Loknatha, Jayarama Shetty, Krishna Prasad, C.R.Tanvir Pasha
- Objective: Overexpression of epidermal growth factor receptor (EGFR) in many cancers makes it an attractive therapeutic target. This study evaluated the clinical utility of nimotuzumab, a monoclonal anti-EGFR antibody, used concurrently with radiotherapy (RT) and chemoradiotherapy (CRT) in squamous cell carcinoma of the head and neck (SCCHN).
- Methods: This open-label study randomized 92 treatment-naïve patients (1:1) with advanced SCCHN into chemoradiation (CRT ± nimotuzumab) or radiation (RT ± nimotuzumab) group by investigator’s discretion; these were further randomized into CRT + nimotuzumab or CRT and RT + nimotuzumab or RT groups, respectively. Treatment included 6 cycles each of cisplatin (50 mg/week), nimotuzumab (200 mg/week), and RT (total dose, 60–66 Gy). Response (tumor size reduction) was assessed at Month 6 post-treatment and survival, at Month 60.